Company News

Share this article:

Abbott opened a nutrition product manufacturing facility in Singapore, in order to meet increasing regional demand for its pediatric products, including Similac, according to company statement. The facility represents the company's largest nutrition investment to date, at $300 million. According to Abbott, the facility will serve up to one million Asian infants and children each year.

 

FDA halted the review of all NDA's received from a Ranbaxy Laboratories plant in India, after discovering falsified data. In a letter to Ranbaxy, CDER director Janet Woodcock said the findings “indicate a pattern and practice of submitting untrue statements of material fact and other wrongful conduct, which raise significant questions regarding the reliability of the data and information contained in applications (pending and approved) that [Ranbaxy] has filed with the agency and which contain data developed at the Ranbaxy Laboratories, Paonta Sahib site.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters